source
- Psychedelic therapeutics near first FDA approval as Compass Pathways and Definium report promising resultsBioSpace notes that the psychedelic drug sector is regaining momentum after a setback in 2024 when Lykos’ MDMA therapy failed to win FDA clearance. The focus has shifted to new candidates, with Com…
- Novo signs $1.4 billion deal with Orbis Medicines to develop oral macrocycle cardiometabolic drugsNovo, which recently rebranded from Novo Nordisk, announced a partnership with Copenhagen‑based Orbis Medicines. The agreement could provide up to $1.4 billion in upfront payments and milestone pay…